TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

On a per-share basis, the Morrisville, New York-based company said it had profit of 2 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The S&P 500 financial sector shows a 0.4% decline. [BRIEFING.COM] The stock market settled into a steady decline. The S&P 500 moved below the 6,000 level early on and continues to fall. Weakness in ...

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 4.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?